S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Detecting Cancer in Mere Seconds: Early Investment Opportunity (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
Detecting Cancer in Mere Seconds: Early Investment Opportunity (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Wall Street inches lower as retailers post holiday numbers
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Detecting Cancer in Mere Seconds: Early Investment Opportunity (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
Detecting Cancer in Mere Seconds: Early Investment Opportunity (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Wall Street inches lower as retailers post holiday numbers
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Detecting Cancer in Mere Seconds: Early Investment Opportunity (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
Detecting Cancer in Mere Seconds: Early Investment Opportunity (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Wall Street inches lower as retailers post holiday numbers
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Detecting Cancer in Mere Seconds: Early Investment Opportunity (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
Detecting Cancer in Mere Seconds: Early Investment Opportunity (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Wall Street inches lower as retailers post holiday numbers
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
NASDAQ:CYCN

Cyclerion Therapeutics (CYCN) Stock Price, News & Analysis

$3.20
+0.04 (+1.27%)
(As of 03/4/2024 ET)
Today's Range
$3.07
$3.44
50-Day Range
$2.78
$4.32
52-Week Range
$1.75
$13.38
Volume
1,560 shs
Average Volume
3,056 shs
Market Capitalization
$7.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CYCN stock logo

About Cyclerion Therapeutics Stock (NASDAQ:CYCN)

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is Zagociguat (CY6463), a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018, a CNS-targeted sGC stimulator that is in preclinical trial for the treatment of neuropsychiatric diseases and disorders. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

CYCN Stock Price History

CYCN Stock News Headlines

Cyclerion Therapeutics, Inc. (CYCN)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
CYCN - Cyclerion Therapeutics, Inc.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Cyclerion Shares Rise After Spurned Bid for Assets
Cyclerion Rejects Unsolicited Proposal To Buy Its Assets
See More Headlines
Receive CYCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/05/2024
Next Earnings (Estimated)
3/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CYCN
Fax
N/A
Employees
16
Year Founded
N/A

Profitability

Net Income
$-44,080,000.00
Pretax Margin
-4,991.45%

Debt

Sales & Book Value

Annual Sales
$1.62 million
Book Value
$4.81 per share

Miscellaneous

Free Float
2,125,000
Market Cap
$7.84 million
Optionable
No Data
Beta
1.83
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report














CYCN Stock Analysis - Frequently Asked Questions

How have CYCN shares performed in 2024?

Cyclerion Therapeutics' stock was trading at $3.35 at the beginning of the year. Since then, CYCN shares have decreased by 4.5% and is now trading at $3.20.
View the best growth stocks for 2024 here
.

Are investors shorting Cyclerion Therapeutics?

Cyclerion Therapeutics saw a increase in short interest in February. As of February 15th, there was short interest totaling 26,800 shares, an increase of 9.8% from the January 31st total of 24,400 shares. Based on an average trading volume of 7,500 shares, the short-interest ratio is presently 3.6 days. Currently, 1.6% of the shares of the stock are short sold.
View Cyclerion Therapeutics' Short Interest
.

When is Cyclerion Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our CYCN earnings forecast
.

How were Cyclerion Therapeutics' earnings last quarter?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) issued its quarterly earnings data on Tuesday, November, 9th. The company reported ($5.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($7.00) by $1.80. The company earned $0.35 million during the quarter, compared to the consensus estimate of $3 million.

When did Cyclerion Therapeutics' stock split?

Cyclerion Therapeutics shares reverse split before market open on Tuesday, May 16th 2023. The 1-20 reverse split was announced on Tuesday, May 16th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 16th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Cyclerion Therapeutics own?
Who are Cyclerion Therapeutics' major shareholders?

Cyclerion Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Tyndall Capital Partners L P (6.71%), Vanguard Group Inc. (0.96%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Peter M Hecht, Peter M Hecht, Slate Path Capital Lp and Terrance Mcguire.
View institutional ownership trends
.

How do I buy shares of Cyclerion Therapeutics?

Shares of CYCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CYCN) was last updated on 3/5/2024 by MarketBeat.com Staff